KIT and gastrointestinal stromal tumor: Although initial preclinical data suggested activity of ripretinib against primary oncogenic mutations as well as secondary resistance mutations in the ATP pocket and activation loop of KIT (15), a phase III trial for second-line therapy of patients with advanced GIST failed to meet its primary PFS endpoint when compared with sunitinib (16).